Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobody
Despite unprecedented global efforts to rapidly develop SARS-CoV-2 treatments, in order to
reduce the burden placed on health systems, the situation remains critical. Effective …
reduce the burden placed on health systems, the situation remains critical. Effective …
Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice
P Pymm, A Adair, LJ Chan… - Proceedings of the …, 2021 - National Acad Sciences
Neutralizing antibodies are important for immunity against SARS-CoV-2 and as therapeutics
for the prevention and treatment of COVID-19. Here, we identified high-affinity nanobodies …
for the prevention and treatment of COVID-19. Here, we identified high-affinity nanobodies …
A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo
L Hanke, H Das, DJ Sheward… - Nature …, 2022 - nature.com
Antibodies binding to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
spike have therapeutic promise, but emerging variants show the potential for virus escape …
spike have therapeutic promise, but emerging variants show the potential for virus escape …
A multivalent and thermostable nanobody neutralizing SARS-CoV-2 omicron (B. 1.1. 529)
Y Lu, Q Li, H Fan, C Liao, J Zhang, H Hu… - International Journal …, 2023 - Taylor & Francis
Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron
variants have risen to dominance, which contains far more mutations in the spike protein in …
variants have risen to dominance, which contains far more mutations in the spike protein in …
Arsenal of nanobodies shows broad-spectrum neutralization against SARS-CoV-2 variants of concern in vitro and in vivo in hamster models
Nanobodies offer several potential advantages over mAbs for the control of SARS-CoV-2.
Their ability to access cryptic epitopes conserved across SARS-CoV-2 variants of concern …
Their ability to access cryptic epitopes conserved across SARS-CoV-2 variants of concern …
[HTML][HTML] A nanobody recognizes a unique conserved epitope and potently neutralizes SARS-CoV-2 omicron variants
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) Omicron variant sub-
lineages spread rapidly worldwide, mostly due to their immune-evasive properties. This has …
lineages spread rapidly worldwide, mostly due to their immune-evasive properties. This has …
Engineered multivalent nanobodies potently and broadly neutralize SARS‐CoV‐2 variants
JM Zupancic, JS Schardt, AA Desai… - Advanced …, 2021 - Wiley Online Library
The COVID‐19 pandemic continues to be a severe threat to human health, especially due to
current and emerging SARS‐CoV‐2 variants with potential to escape humoral immunity …
current and emerging SARS‐CoV‐2 variants with potential to escape humoral immunity …
A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants
The spike glycoprotein of SARS-CoV-2 engages with human ACE 2 to facilitate infection.
Here, we describe an alpaca-derived heavy chain antibody fragment (VHH), saRBD-1, that …
Here, we describe an alpaca-derived heavy chain antibody fragment (VHH), saRBD-1, that …
The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization
The severe acute respiratory syndrome (SARS-CoV-2), a newly emerging of coronavirus,
continues to infect humans in the absence of a viable treatment. Neutralizing antibodies that …
continues to infect humans in the absence of a viable treatment. Neutralizing antibodies that …
Rapid development of neutralizing and diagnostic SARS-COV-2 mouse monoclonal antibodies
AP Chapman, X Tang, JR Lee, A Chida, K Mercer… - Scientific reports, 2021 - nature.com
The need for high-affinity, SARS-CoV-2-specific monoclonal antibodies (mAbs) is critical in
the face of the global COVID-19 pandemic, as such reagents can have important diagnostic …
the face of the global COVID-19 pandemic, as such reagents can have important diagnostic …
相关搜索
- sars cov g614 variants
- sars cov potent neutralization
- sars cov clinical isolates
- g614 variants potent neutralization
- g614 variants clinical isolates
- clinical isolates potent neutralization
- sars cov rapid development
- sars cov use of nanobodies
- sars cov monoclonal antibodies
- sars cov elisa test
- sars cov omicron variants
- sars cov multivalent nanobodies